These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33910624)

  • 1. EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?
    Schmidt L; Sehic O; Wild C
    J Pharm Policy Pract; 2021 Apr; 14(1):37. PubMed ID: 33910624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counting the cost of public and philanthropic R&D funding: the case of olaparib.
    Schmidt L; Sehic O; Wild C
    J Pharm Policy Pract; 2022 Aug; 15(1):47. PubMed ID: 35974344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Return on investment in science: twenty years of European Commission funded research in Alzheimer's dementia, breast cancer and prostate cancer.
    Jakovljevic M; Deceuninck P; Pistollato F; Daskalopoulos E; Bernasconi C; Carausu F; Rosa M; Progri A; Makarieva M; Krstic K
    Cost Eff Resour Alloc; 2024 Jun; 22(1):51. PubMed ID: 38880873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Union investment and countries' involvement in mental health research between 2007 and 2013.
    Hazo JB; Gervaix J; Gandré C; Brunn M; Leboyer M; Chevreul K
    Acta Psychiatr Scand; 2016 Aug; 134(2):138-49. PubMed ID: 27145870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus document on European brain research.
    Olesen J; Baker MG; Freund T; di Luca M; Mendlewicz J; Ragan I; Westphal M
    J Neurol Neurosurg Psychiatry; 2006 Aug; 77 Suppl 1(Suppl 1):i1-49. PubMed ID: 16845120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Market access pathways for cell therapies in France.
    Rémuzat C; Toumi M; Jørgensen J; Kefalas P
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines.
    Ruggieri L; Giannuzzi V; Baiardi P; Bonifazi F; Davies EH; Giaquinto C; Bonifazi D; Felisi M; Chiron C; Pressler R; Rabe H; Whitaker MJ; Neubert A; Jacqz-Aigrain E; Eichler I; Turner MA; Ceci A;
    Eur J Pediatr; 2015 Apr; 174(4):481-91. PubMed ID: 25241827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing European Support for Neglected Infectious Disease Research.
    Olesen OF; Ackermann M
    Comput Struct Biotechnol J; 2017; 15():180-184. PubMed ID: 28179980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic and clinical proteomics from the EU Health Research perspective.
    Dyląg T; Jehenson P; van de Loo JW; Sanne JL
    Proteomics Clin Appl; 2010 Dec; 4(12):888-91. PubMed ID: 21179890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study.
    Bragginton EC; Piddock LJ
    Lancet Infect Dis; 2014 Sep; 14(9):857-68. PubMed ID: 25065509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The European challenges of funding orphan medicinal products.
    Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
    Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research investments for UK infectious disease research 1997-2013: A systematic analysis of awards to UK institutions alongside national burden of disease.
    Head MG; Brown RJ; Clarke SC
    J Infect; 2018 Jan; 76(1):11-19. PubMed ID: 29061335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.
    Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D
    Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishing ophthalmology in the research framework programs of the European Union].
    Scholl HP; Wheeler-Schilling TH; Zrenner E; Holz FG
    Ophthalmologe; 2006 Feb; 103(2):91-9. PubMed ID: 16437232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.